Hamilton-based McMaster start-up secures $105M (USD) to commercialize potential cancer treatment
From left to right, John Valiant, Fusion’s Chief Executive Officer, with Dr. Merrilee Fullerton, Minister of Training, Colleges and Universities, at the announcement of $105 million USD in funding for Fusion Pharmaceuticals. Photo by Georgia Kirkos.
April 3, 2019
Fusion Pharmaceuticals, a biopharmaceutical company founded at McMaster University and based at the McMaster Innovation Park (MIP), has secured $105M (USD) in private financing to help advance a new approach to cancer therapy based on its ground-breaking research.
This new round of funding, which follows earlier investments of $46M (USD), comes from an international syndicate of leading investors. The funds will help advance the work of the company, including growing its operations in Hamilton.
The company was spun off from the Centre for Probe Development and Commercialization (CPDC), which is located at McMaster. Fusion’s Chief Executive Officer is John Valliant, a professor of chemistry and chemical biology at McMaster.
“We have made tremendous progress in the last two years and this financing reflects strong support for our work, our people and product pipeline,” Valliant says. “With this investment, we will be able to broaden our team and clinical program and accelerate our strategies to develop new therapies.”
The unprecedented $105M USD will help advance a new approach to cancer therapy based on @FusionPharmaInc ground-breaking research. Fusion’s lead product seeks out and infiltrates cancer cells and delivers a highly localized radiation dose that targets the DNA of cancer cells.
— McMaster University (@McMasterU) April 3, 2019
Fusion’s lead product is designed to seek out and infiltrate cancer cells and deliver a lethal and highly localized dose of radiation. Its aim is to target and damage the very DNA of the cancer cells so they cannot grow back. It is designed to attack drug-resistant tumours that do not respond to traditional therapies, which may include lung, prostate, breast and colorectal cancers.
As a doctor, I'm keenly aware of importance of scientific and medical research, says @DrFullertonMPP. And John Valliant's innovative cancer treament is truly remarkable. #BRighterWorld
— McMaster University (@McMasterU) April 3, 2019
“This is a remarkable accomplishment by our colleagues at Fusion,” says Rob Baker, McMaster vice-president, research. “First and foremost, their work has the potential to improve the health and well-being of many cancer patients. It’s also a true indicator that the plan to grow Hamilton’s life sciences sector by commercializing McMaster’s research is achieving real results.”
The Series B financing is being led by lead investors Varian and OrbiMed and includes US, Canadian, Irish and Swedish investors.
“The world is learning that Hamilton is a great place to grow a life sciences business,” says Ty Shattuck, CEO of the McMaster Innovation Park. “Fusion Pharmaceuticals is a homegrown global success story and it paves the way for even more growth and opportunity in this sector for Hamilton and our business community.”
It’s been a year of great accomplishment for Fusion. In 2018, it was recognized as Ontario’s Life Sciences Company of the Year. The award recognizes an Ontario-based company that demonstrates strong leadership and is achieving significant milestones in life sciences research and development and is working to commercialize innovative products.
